Phase I trial of high-dose melphalan, high-dose etoposide and autologous bone marrow re-infusion in solid tumors: an Eastern Cooperative Oncology Group (ECOG) study.


:The purpose of this work was to determine the maximum tolerated (phase II) dose of melphalan and etoposide that can be given in conjunction with autologous BM re-infusion in patients who have refractory or relapsed solid tumors. Twenty-six patients with refractory or relapsed breast cancer (n = 15), small cell lung cancer (n = 1), ovarian cancer (n = 3), colorectal cancer (n = 3) or malignant melanoma (n = 4) were enrolled and treated in this phase I study. Patients ranged in age from 31 to 60 years (median 44.5 years). Melphalan 180 mg/m2 (60 mg/m2/day for 3 consecutive days i.v. over 30 min) and etoposide 1200-3600 mg/m2 (400-1200 mg/m2/day for 3 consecutive days i.v. over 4 h) were given followed by autologous BM infusion 60-72 h after completion of chemotherapy. Ten patients received GM-CSF or G-CSF therapy after marrow re-infusion. Regimen-related toxicities included fever, pancytopenia, mucositis, nausea, vomiting, diarrhea, esophagitis, hepatic dysfunction and infection. Neutrophils recovered to > 500 x 10(6)/l and platelets recovered to > 20 x 10(9)/l (without transfusions) a median of 17 days and 20.5 days after marrow infusion, respectively. Dose-limiting toxicity occurred at an etoposide dose of 3600 mg/m2, since 4 of 6 patients treated at this dose level experienced grade 4 NCI Common Toxicity Criteria (mucositis (n = 3) and infection (n = 1)). Complete responses were noted in 7 patients (breast cancer (n = 5), colorectal cancer (n = 1) and melanoma (n = 1)); partial responses were observed in 5 patients. Melphalan 180 mg/m2 and etoposide 3000 mg/m2 is a potent high-dose chemotherapy regimen with significant antineoplastic activity, particularly for breast cancer, and has acceptable toxicity when administered in conjunction with autologous BM re-infusion.


Bone Marrow Transplant


Lazarus HM,Gray R,Ciobanu N,Winter J,Weiner RS


Has Abstract


1994-09-01 00:00:00












  • Low bone mineral density is associated with insulin resistance in bone marrow transplant subjects.

    abstract::Post-BMT subjects have an increased bone fracture risk. Additionally, several factors were associated with osteopenia and osteoporosis in these individuals. We aimed to identify other factors associated with osteopenia and osteoporosis in allogeneic post-BMT subjects. We conducted a cross-sectional study with 47 allog...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章


    authors: Faulhaber GA,Premaor MO,Moser Filho HL,Silla LM,Furlanetto TW

    更新日期:2009-06-01 00:00:00

  • Late cytomegalovirus polyradiculopathy following haploidentical CD34+-selected hematopoietic stem cell transplantation.

    abstract::A 55-year-old man with acute myeloid leukemia in second relapse presented 4 months after haploidentical CD34+-selected hematopoietic stem cell transplantation (HSCT) with symmetric, progressive neurological deficits of the lower extremities. Although there was no molecular evidence for drug resistance in the cerebral-...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章


    authors: Zeiser R,Grüllich C,Bertz H,Pantazis G,Hufert FT,Bley TA,Finke J

    更新日期:2004-01-01 00:00:00

  • Similar outcomes between adolescent/young adults and children with AML following allogeneic hematopoietic cell transplantation.

    abstract::We recently reported that adolescents and young adults (AYAs) with B-cell ALL receiving allogeneic hematopoietic cell transplantation (allo-HCT) have inferior survival compared with children, primarily because of greater TRM. We therefore hypothesized that in the setting of allo-HCT for AML, similar inferior outcomes ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章


    authors: Burke MJ,Gossai N,Cao Q,Macmillan ML,Warlick E,Verneris MR

    更新日期:2014-02-01 00:00:00

  • Predicting the severity of graft-versus-host disease from interleukin-10 levels after bone marrow transplantation.

    abstract::Acute graft-versus-host disease (GVHD) is the most important complication of allogeneic bone marrow transplantation. We investigated the possibility of predicting severe acute GVHD using plasma interleukin-10 levels in 31 patients who underwent allogeneic bone marrow transplantation. In patients with acute GVHD, the i...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章


    authors: Takatsuka H,Takemoto Y,Okamoto T,Fujimori Y,Tamura S,Wada H,Okada M,Yamada S,Kanamaru A,Kakishita E

    更新日期:1999-11-01 00:00:00

  • Blood and marrow transplantation during the emerging COVID-19 pandemic: the Seattle approach.

    abstract::On January 20, 2020, the first patient with coronavirus disease 2019 (COVID-19) in the United States of America was diagnosed in Washington state, which subsequently experienced rapidly increasing numbers of COVID-19 cases, hospitalizations, and deaths. This placed the Seattle Blood and Marrow Transplant Program at Fr...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,评审


    authors: Ueda Oshima M,Sandmaier BM,Petersdorf E,Flowers ME,Hill GR,Lee SJ,Appelbaum FR,Carpenter PA,Baker KS,Connelly-Smith L,McCool A,Elgar S,Pergam SA,Liu C,Stewart FM,Mielcarek M

    更新日期:2020-09-26 00:00:00

  • GM-CSF-mobilized peripheral blood CD34+ cells differ from steady-state bone marrow CD34+ cells in adhesion molecule expression.

    abstract::To determine the effect of growth factor mobilization on the expression of adhesion molecules, we compared CD34+ progenitor cell (PC) populations from steady-state bone marrow (BM) with granulocyte-macrophage colony-stimulating factor (GM-CSF)-mobilized apheresis products (peripheral blood stem cell (PSC)) using flow ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章


    authors: Watanabe T,Dave B,Heimann DG,Lethaby E,Kessinger A,Talmadge JE

    更新日期:1997-06-01 00:00:00

  • Topical issues in unrelated donor haematopoietic stem cell transplants: a report from a workshop convened by the Anthony Nolan Trust in London - 2005.

    abstract::Over more than three decades, The Anthony Nolan Trust (ANT) has provided an unrelated donor (UD) for over 4000 children and adults lacking a suitable family member donor, and has remained at the forefront of developments in haematopoietic stem cell transplantation (HSCT) and bone marrow register management. These thre...

    journal_title:Bone marrow transplantation



    authors: Duarte RF,Pamphilon D,Cornish J,Shaw BE,Samson D,Craddock C,Marks D,Mufti GJ,Powles RL,Apperley JF,Madrigal JA,Goldman JM

    更新日期:2006-05-01 00:00:00

  • Dose-reduced conditioning for allogeneic blood stem cell transplantation: durable engraftment without antithymocyte globulin.

    abstract::Between February 1998 and October 1999, 24 patients with advanced leukemia, lymphoma or solid tumors received G-CSF mobilized peripheral blood stem cells (PBSC) from HLA-matched sibling donors after dose-reduced conditioning therapy. Only patients with reduced performance status or major infectious complications, not ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章


    authors: Bornhäuser M,Thiede C,Schuler U,Platzbecker U,Freiberg-Richter J,Helwig A,Plettig R,Röllig C,Naumann R,Kroschinsky F,Neubauer A,Ehninger G

    更新日期:2000-07-01 00:00:00

  • Production of IL-10 by alloreactive sibling donor cells and its influence on the development of acute GVHD.

    abstract::Graft-versus-host disease (GVHD) is a major complication of allogeneic hematopoietic stem cell transplantation. Pretransplant conditioning regimes cause release of proinflammatory cytokines that stimulate alloreactive donor T cells to attack recipient tissues. IL-10 has been shown to directly downregulate CD4+ T cells...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章


    authors: Weston LE,Geczy AF,Briscoe H

    更新日期:2006-01-01 00:00:00

  • Tacrolimus (FK506) and methotrexate regimens to prevent graft-versus-host disease after unrelated dog leukocyte antigen (DLA) nonidentical marrow transplantation.

    abstract::We previously reported an synergism between methotrexate and tacrolimus (FK506) in preventing graft-versus-host disease (GVHD) in dogs given DLA-nonidentical unrelated marrow grafts after 9.2 Gy of total body irradiation (TBI). Methotrexate was given at 0.4 mg/kg i.v. on days 1, 3, 6 and 11 and FK506 at 0.15 mg/kg/day...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章


    authors: Yu C,Storb R,Deeg HJ,Graham TC,Scheuning FG,Huss R,Seidel K,Fitzsimmons WE

    更新日期:1996-04-01 00:00:00

  • Hematopoietic stem cell transplantation in Oman.

    abstract::Hematopoietic SCT (HSCT) is an integral part of the management of patients with hematologic disorders. The Sultanate of Oman, with a population of 2.3 million, has an HSCT program based in the Sultan Qaboos University (SQU) hospital. Initiated in 1995, this two-bed unit continues to be the only program in the country....

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章


    authors: Dennison D,Al Kindi S,Pathare A,Daar S,Nusrat N,Ur Rehman J,Zia F,Khan H,Khan MI,Alghazaly A,Al Zadjali S,Tauro M,Al Lawatia A,Ganguly S

    更新日期:2008-08-01 00:00:00

  • Scoring system for clinically significant CMV infection in seropositive recipients following allogenic hematopoietic cell transplant: an SFGM-TC study.

    abstract::In order to identify cytomegalovirus (CMV)-seropositive patients who are at risk of developing CMV infection following first allogeneic hematopoietic cell transplantation (allo-HCT), we built up a scoring system based on patient/donor characteristics and transplantation modalities. To this end, 3690 consecutive patien...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章


    authors: Beauvais D,Drumez E,Blaise D,Peffault de Latour R,Forcade E,Ceballos P,Uyttebroeck A,Labussière H,Nguyen S,Bourhis JH,Chevallier P,Thiebaut A,Poiré X,Maury S,Deconinck E,Cluzeau T,Brissot E,Huynh A,Rubio MT,Duhamel

    更新日期:2020-12-18 00:00:00

  • Safety of AlloPBPCT donors: biometrical considerations on monitoring long term risks.

    abstract::Up to now there are no data on long-term effects of allogeneic peripheral blood cell transplantation (AlloPBPCT). In particular, long term effects on healthy donors by the mobilization procedure which includes the exposition to G-CSF over several days are unknown. Recently the possibility of an increase in risk for ac...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,评审


    authors: Hasenclever D,Sextro M

    更新日期:1996-03-01 00:00:00

  • Effects of cryopreservation on subsets of fetal liver cells.

    abstract::Human fetal livers from 6 to 13 weeks postconception were analysed before and after cryopreservation. The percentages of cell subsets, detected by MoAbs, did not change significantly after cryopreservation. Compared with BM, fetal liver contained significantly smaller subsets of cells identified by MoAbs, with two exc...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章


    authors: Ek S,Ringdén O,Markling L,Dahlberg N,Pschera H,Seiger A,Sundström E,Westgren M

    更新日期:1993-05-01 00:00:00

  • Patient socioeconomic status as a prognostic factor for allo-SCT.

    abstract::The aim of the present study was to assess the influence of socioeconomic status (SeS) on the outcome of allo-SCT at a Brazilian SCT center. In total, 201 patients receiving HLA-identical related allo-SCTs were studied. The median age was 30 years. Overall, 163 patients had malignancies (CML 68, ALL/AML 63, myelodyspl...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章


    authors: Silla L,Fischer GB,Paz A,Daudt LE,Mitto I,Katz B,da Graça Grossini M,Bittencourt HN,Jochims A,Fogliatto L,Bittar CM,Friedrisch JR,Bittencourt RI

    更新日期:2009-04-01 00:00:00

  • Long-term results of autologous marrow transplantation for relapsed or refractory male or female germ cell tumors.

    abstract::Twenty-one patients with relapsed or refractory germ cell tumors were treated with high-dose chemotherapy and marrow transplantation (HDC/BMT) from 1982-1993. Primary sites of disease were testis (17), ovary (three), and pineal gland (one). Pathology included dysgerminoma (one), choriocarcinoma with adenocarcinoma (on...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章


    authors: Mandanas RA,Saez RA,Epstein RB,Confer DL,Selby GB

    更新日期:1998-03-01 00:00:00

  • Herpes simplex infection of the jejunum occurring in the early post-transplantation period.

    abstract::Reactivation of infections with herpes viruses is a frequent and major cause of morbidity after bone marrow transplantation. In this case report we stress that HSV infections of the colon and small intestine should be considered in the differential diagnosis of diarrhea and intestinal bleeding in the early post-transp...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章


    authors: Kingreen D,Nitsche A,Beyer J,Siegert W

    更新日期:1997-12-01 00:00:00

  • Successful treatment of POEMS syndrome with autologous hematopoietic progenitor cell transplantation.

    abstract::POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes) is a plasma cell dyscrasia that differs substantially from classic multiple myeloma. It is often associated with disabling polyneuropathy in younger patients. Current therapeutic approaches are frequently inadequate ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章


    authors: Hogan WJ,Lacy MQ,Wiseman GA,Fealey RD,Dispenzieri A,Gertz MA

    更新日期:2001-08-01 00:00:00

  • Tandem autologous non-myeloablative allogeneic transplantation in patients with multiple myeloma relapsing after a first high dose therapy.

    abstract::We retrospectively studied a series of 23 patients (median age 50 years, range 29-59 years) with multiple myeloma (MM), treated in first relapse by a sequential autologous-allogeneic tandem approach. Tandem transplantation (TT) consisted in high dose melphalan (HDT) and auto-SCT followed by an (allo-SCT) preceded by t...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章


    authors: Karlin L,Arnulf B,Chevret S,Ades L,Robin M,De Latour RP,Malphettes M,Kabbara N,Asli B,Rocha V,Fermand JP,Socie G

    更新日期:2011-02-01 00:00:00

  • N-acetyl-L-cysteine does not affect the pharmacokinetics or myelosuppressive effect of busulfan during conditioning prior to allogeneic stem cell transplantation.

    abstract::Busulfan is currently used as a main component in the conditioning regimen prior to allogeneic stem cell transplantation (SCT). Several studies have shown a correlation between exposure to busulfan and transplantation-related liver toxicity, such as venoocclusive disease (VOD) in patients undergoing SCT. Busulfan is m...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章


    authors: Sjöö F,Aschan J,Barkholt L,Hassan Z,Ringdén O,Hassan M

    更新日期:2003-08-01 00:00:00

  • Comparing i.v. BU dose intensity between two regimens (FB2 vs FB4) for allogeneic HCT for AML in CR1: a report from the Acute Leukemia Working Party of EBMT.

    abstract::This retrospective analysis compared two regimens of fludarabine combined with i.v. BU 6.4 mg/kg (FB2) or BU 12.8 mg/kg (FB4) for allografting of AML in first CR. A total of 437 patients (median age: 50 years) were administered FB2 (n = 225, 51%) or FB4 (n = 212, 49%). Median follow-up time was 28 months. Use of FB2 r...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,多中心研究


    authors: Kharfan-Dabaja MA,Labopin M,Bazarbachi A,Hamladji RM,Blaise D,Socié G,Lioure B,Bermudez A,Lopez-Corral L,Or R,Arcese W,Fegueux N,Nagler A,Mohty M

    更新日期:2014-09-01 00:00:00

  • Stem cell donor registry activities during the COVID-19 pandemic: a field report by DKMS.

    abstract::The COVID-19 pandemic has serious implications also for patients with other diseases. Here, we describe the effects of the pandemic on unrelated hematopoietic stem cell donation and transplantation from the perspective of DKMS, a large international donor registry. Especially, we cover the development of PBSC and bone...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章


    authors: Mengling T,Rall G,Bernas SN,Astreou N,Bochert S,Boelk T,Buk D,Burkard K,Endert D,Gnant K,Hildebrand S,Köksaldi H,Petit I,Sauter J,Seitz S,Stolze J,Weber K,Weber M,Lange V,Pingel J,Platz A,Schäfer T,Schetelig J

    更新日期:2020-11-20 00:00:00

  • Practices for cytomegalovirus diagnosis, prophylaxis and treatment in allogeneic bone marrow transplant recipients: a report from the Working Party for Infectious Diseases of the EBMT.

    abstract::During the past few years major progress has been made in the diagnosis and therapy of CMV infection after allogeneic BMT. The aim of this survey was to investigate the use of diagnostic techniques, use of prophylaxis and the therapeutic strategies among members of the EBMT. Seventy centers from 20 countries responded...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章


    authors: Ljungman P,De Bock R,Cordonnier C,Einsele H,Engelhard D,Grundy J,Locasciulli A,Reusser P,Ribaud P

    更新日期:1993-10-01 00:00:00

  • Admission of bone marrow transplant recipients to the intensive care unit: outcome, survival and prognostic factors.

    abstract::The role of ICU support in BMT patients is controversial. In an era of constrained resources, the use of prognostic factors predicting outcome may be helpful in identifying patients who are most likely (or unlikely) to benefit from this intervention. We attempted to define the survival of patients admitted to ICU foll...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章


    authors: Jackson SR,Tweeddale MG,Barnett MJ,Spinelli JJ,Sutherland HJ,Reece DE,Klingemann HG,Nantel SH,Fung HC,Toze CL,Phillips GL,Shepherd JD

    更新日期:1998-04-01 00:00:00

  • A prospective study of Epstein-Barr virus load in 85 hematopoietic stem cell transplants.

    abstract::EBV viral load (EBV-VL) in PBMC was prospectively determined by semi-quantitative PCR in 85 stem cell transplants (40 genoidentical, 45 non-genoidentical) in order to characterize the kinetics of EBV-VL and to assess the ability of this measure to predict the development of EBV-induced lymphoproliferative disease (EBV...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章


    authors: Sirvent-Von Bueltzingsloewen A,Morand P,Buisson M,Souillet G,Chambost H,Bosson JL,Bordigoni P

    更新日期:2002-01-01 00:00:00

  • Randomized comparison of early and late vaccination with inactivated poliovirus vaccine after allogeneic BMT.

    abstract::Forty-five adult HLA-matched sibling BMT recipients were randomized to receive inactivated poliovirus vaccine (IPV) at 6, 8 and 14 months (early group, n = 23) or at 18, 20 and 26 months after BMT (late group, n = 22). Ninety-five percent of the early group patients had protective antibody titres of > or = 4 to poliov...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章,随机对照试验


    authors: Parkkali T,Stenvik M,Ruutu T,Hovi T,Volin L,Ruutu P

    更新日期:1997-10-01 00:00:00

  • Pegfilgrastim vs filgrastim in PBSC mobilization for autologous hematopoietic SCT: a systematic review and meta-analysis.

    abstract::Trial outcomes comparing cytokine agents for PBSC mobilization in autologous hematopoietic transplant patients have been controversial. We performed a systematic review and meta-analysis of evidence available on pegfilgrastim vs filgrastim in chemo-cytokine mobilization. Electronic literature searches of PubMed, EMBAS...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,meta分析,评审


    authors: Kim MG,Han N,Lee EK,Kim T

    更新日期:2015-04-01 00:00:00

  • Safety and preliminary efficacy of plerixafor (Mozobil) in combination with chemotherapy and G-CSF: an open-label, multicenter, exploratory trial in patients with multiple myeloma and non-Hodgkin's lymphoma undergoing stem cell mobilization.

    abstract::Plerixafor, a novel CXCR4 inhibitor, is effective in mobilizing PBSCs particularly when used in conjunction with G-CSF. In four cohorts, this pilot study explored the safety of plerixafor mobilization when incorporated into a conventional stem cell mobilization regimen of chemotherapy and G-CSF. Forty (26 multiple mye...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章,多中心研究


    authors: Dugan MJ,Maziarz RT,Bensinger WI,Nademanee A,Liesveld J,Badel K,Dehner C,Gibney C,Bridger G,Calandra G

    更新日期:2010-01-01 00:00:00

  • Allogeneic peripheral blood stem cell transplantation from two- or three-loci-mismatched related donors in adult Japanese patients with high-risk hematologic malignancies.

    abstract::With the increasing frequency of haploidentical transplantation, it is becoming more important to establish the degree of HLA mismatch that can be accepted. We retrospectively analyzed clinical data of 50 adult Japanese patients with high-risk hematologic malignancies who underwent allogeneic peripheral blood stem cel...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章


    authors: Yamasaki S,Ohno Y,Taniguchi S,Yoshida T,Hayashi S,Ogawa H,Shimazaki C,Takahashi S,Kasai M,Wake A,Nishimura M,Tokunaga K,Gondo H,Takaue Y,Harada M,Mineishi S,Japanese group for blood and marrow transplantation.

    更新日期:2004-02-01 00:00:00

  • G-CSF alone vs cyclophosphamide plus G-CSF in PBPC mobilization of patients with lymphoma: results depend on degree of previous pretreatment.

    abstract::We performed a randomized study to compare 'G-CSF alone' (administered at dose of 10 mcg/kg/day) and 'cyclophosphamide plus G-CSF' (cyclophosphamide at dose of 4 g/m(2) and G-CSF at dose of 10 microg/kg/day), as PBPC mobilization schedules in 52 patients with NHL or HD. Randomization was stratified according to the am...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章,随机对照试验


    authors: Milone G,Leotta S,Indelicato F,Mercurio S,Moschetti G,Di Raimondo F,Tornello A,Consoli U,Guido G,Giustolisi R

    更新日期:2003-05-01 00:00:00